ClinicalTrials.gov
ClinicalTrials.gov Menu

A First-In-Human Study With a Single Ascending Dose of UCB7858 in Healthy Volunteers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02879877
Recruitment Status : Completed
First Posted : August 26, 2016
Last Update Posted : February 8, 2018
Sponsor:
Information provided by (Responsible Party):
UCB Pharma ( UCB Biopharma S.P.R.L. )

Brief Summary:
This study is designed to evaluate the safety and tolerability of UCB7858 when given as single ascending doses administered by intravenous or subcutaneous infusion in healthy subjects.

Condition or disease Intervention/treatment Phase
Healthy Volunteers Drug: UCB7858 Drug: Placebo Phase 1

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 78 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Basic Science
Official Title: A Subject-blind, Investigator-blind, Randomized, Placebo-controlled, First-in-human Study Evaluating the Safety/Tolerability, Pharmacokinetics, Effect on Transglutaminase 2 Expression, and Occupancy of Single Ascending Intravenous and Subcutaneous Doses of UCB7858 in Healthy Subjects
Actual Study Start Date : July 11, 2016
Actual Primary Completion Date : January 31, 2018
Actual Study Completion Date : January 31, 2018

Arm Intervention/treatment
Experimental: UCB7858 (intravenous)
Various single doses, administered to various cohorts.
Drug: UCB7858
Placebo Comparator: Placebo (intravenous)
Single dose placebo comparator for each cohort of iv administration.
Drug: Placebo
Experimental: UCB7858 (subcutaneous)
Various single doses, administered to various cohorts.
Drug: UCB7858
Placebo Comparator: Placebo (subcutaneous)
Single dose placebo comparator for each cohort of sc administration.
Drug: Placebo



Primary Outcome Measures :
  1. Incidence of adverse events following administration of UCB7858 [ Time Frame: Cohort 1-10: Day 1 up to Day 72 Cohort 11: Day 1 up to Day 120 ]

Secondary Outcome Measures :
  1. Maximum plasma concentration (Cmax) [ Time Frame: Cohort 1-10: Predose (Day 1) up to Day 72 Cohort 11: Predose (Day 1) up to Day 120 ]
  2. Time to reach Cmax (tmax) [ Time Frame: Cohort 1-10: Predose (Day 1) up to Day 72 Cohort 11: Predose (Day 1) up to Day 120 ]
  3. Area under the curve from time 0 to time t, the time of last quantifiable concentration [AUC(0-t)] [ Time Frame: Cohort 1-10: Predose (Day 1) up to Day 72 Cohort 11: Predose (Day 1) up to Day 120 ]
  4. Area under the curve from 0 to infinity (AUC) [ Time Frame: Cohort 1-10: Predose (Day 1) up to Day 72 Cohort 11: Predose (Day 1) up to Day 120 ]
  5. The terminal plasma half-life (t1/2) following intravenous administration [ Time Frame: Cohort 1-10: Predose (Day 1) up to Day 72 Cohort 11: Predose (Day 1) up to Day 120 ]
  6. Plasma clearance (CL) of UCB7858 following intravenous administration [ Time Frame: Cohort 1-10: Predose (Day 1) up to Day 72 Cohort 11: Predose (Day 1) up to Day 120 ]
  7. Volume of distribution (Vss) for UCB7858 at steady state following intravenous administration [ Time Frame: Cohort 1-10: Predose (Day 1) up to Day 72 Cohort 11: Predose (Day 1) up to Day 120 ]
  8. Apparent volume of distribution (Vss/F) of UCB7858 following subcutaneous administration [ Time Frame: Cohort 1-10: Predose (Day 1) up to Day 72 Cohort 11: Predose (Day 1) up to Day 120 ]
  9. Apparent plasma clearance (CL/F) of UCB7858 following subcutaneous administration [ Time Frame: Cohort 1-10: Predose (Day 1) up to Day 72 Cohort 11: Predose (Day 1) up to Day 120 ]
  10. Mean absolute bioavailability (F) of UCB7858 given subcutaneously, using the ratio of geometric mean AUCs for subcutaneous (sc) administration and intravenous (iv) infusion (AUC_sc/AUC_iv) [ Time Frame: Cohort 1-10: Predose (Day 1) up to Day 72 Cohort 11: Predose (Day 1) up to Day 120 ]
  11. Concentration of UCB7858 at the end of infusion (Cinf) [ Time Frame: Cohort 1-10: Predose (Day 1) up to Day 72 Cohort 11: Predose (Day 1) up to Day 120 ]
  12. Time at the end of infusion of UCB7858 (tinf) [ Time Frame: Cohort 1-10: Predose (Day 1) up to Day 72 Cohort 11: Predose (Day 1) up to Day 120 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy male and female volunteers who gave their written consent by signing the Informed Consent Form
  • Subjects in the age between 18 and 55 years old with normal weight as determined by a body mass index (BMI) between 18 and 30 kg/m^2, with a body weight of at least 50 kg for male subjects or 45 kg for female subjects
  • Subject has clinical laboratory test results within the reference ranges of the testing laboratory or outside the reference range of the laboratory but considered as not clinically significant by the Investigator
  • Subjects has blood pressure (BP) and pulse within normal range in a supine position after 5 minutes rest
  • Subject's electrocardiogram (ECG) is considered normal or abnormal but clinically non significant
  • Female subjects of childbearing potential must agree to use a highly effective method of birth control during the study and for a period of 6 months after dosing of IMP

Exclusion Criteria:

  • Subject has any medical or psychiatric condition that, in the opinion of the Investigator, could jeopardize or would compromise the subject's ability to participate in this study: Subject has any acute or chronic illness which, in the opinion of the Investigator, may place the subject at risk because of participation in the study. Subject has any clinically relevant abnormal findings in physical examination, laboratory tests, vital signs, or ECG, which, in the opinion of the Investigator, may place the subject at risk because of participation in the study.
  • Tests positive for Human Immunodeficiency Virus (HIV)-1 or-2 antibodies, Hepatitis B Virus (HBV) surface antigen, or Hepatitis C Virus (HCV) antibody at Screening
  • Any of the following hematological function tests at the Screening Visit: Hemoglobin <111g/L (for women) or <113g/L (for men)
  • Absolute neutrophil count <1.5x10^9/L (<1000/mm^3); Platelets <150x10^9/L
  • Female subject who is breastfeeding, pregnant, or plans to become pregnant during the study or within 6 months following the final dose of the IMP

For subjects enrolled in the cohorts where the skin biopsies will be performed (Cohort 7 onward), the following exclusion criteria will also apply:

  • Subject has a known hypersensitivity to dressings, local anesthetics, suture material, or relevant local/oral antibiotic therapy
  • Subject has or had a history of a known inflammatory dermatological condition including eczema, atopic dermatitis, candidiasis, psoriasis, recurrent or persistent fungal infection, or bacterial infections
  • Subject uses steroid or nonsteroidal anti-inflammatory drug (NSAID)-containing skin creams on a regular basis
  • Subject has used NSAID or NSAID-containing medications within 7 days of randomization
  • Subject has used skin emollients within 7 days of randomization on the area of the skin from buttocks
  • Subject has tattoos, nevi, or other skin abnormalities such as keloids (or history of keloids, folliculitis, or acne vulgaris) that may, in the opinion of the Investigator, interfere with study assessments.
  • Subject has been participating in recreational sun-bathing, or use of sun-bed, on the area of the skin from buttocks within 7 days of Screening
  • Subject has active neoplastic disease or history of neoplastic disease within 5 years of the Screening Visit
  • Subject has a history of moderate to severe allergic reaction to medication(s) including biologics (for subjects in Cohort 11 only).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02879877


Locations
United Kingdom
Up0029 001
London, United Kingdom
Sponsors and Collaborators
UCB Biopharma S.P.R.L.
Investigators
Study Director: UCB Cares UCB (+1 844 599 2273)

Responsible Party: UCB Biopharma S.P.R.L.
ClinicalTrials.gov Identifier: NCT02879877     History of Changes
Other Study ID Numbers: UP0029
2016-001129-15 ( EudraCT Number )
First Posted: August 26, 2016    Key Record Dates
Last Update Posted: February 8, 2018
Last Verified: February 2018

Keywords provided by UCB Pharma ( UCB Biopharma S.P.R.L. ):
First in human
subjects